- Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
-
Lim SW, Jin JZ, Jin L, Jin J, Li C
- KMID: 2381580
- Korean J Intern Med.
- 2015 Nov;30(6):759-770.
- doi: 10.3904/kjim.2015.30.6.759
Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and... -
- CITED
-
- Close
- SHARE
-
- Close
- Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
-
Broxmeyer
- KMID: 1780121
- Korean J Intern Med.
- 2013 Nov;28(6):639-645.
- doi: 10.3904/kjim.2013.28.6.639
Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
-
Oh TJ, Jung HS, Bae JH, Kim YG, Park KS, Cho YM, Park KS, Kim SY
- KMID: 2158036
- J Korean Med Sci.
- 2013 Jun;28(6):881-887.
- doi: 10.3346/jkms.2013.28.6.881
We investigated characteristics associated with the efficacy of dipeptidyl peptidase-4 inhibitors (DPP4i) in Korean patients with type 2 diabetes. We reviewed medical records of 477 patients who had taken sitagliptin... -
- CITED
-
- Close
- SHARE
-
- Close
